Biomolecular Life Holdings, Inc. (BIOM) Agrees to Acquire Strategic Land in Llanogrande to Develop High-Tech Biomolecular Wellness and Longevity Retreat Near Medellín's International Airport

BIOM plans a related-party land deal for a luxury wellness retreat in Colombia, targeting 2028 opening.

What the company is saying

Biomolecular Life Holdings, Inc. (OTC:BIOM) announces it has agreed to acquire land in Llanogrande, Colombia, for a planned Biomolecular Wellness Spa and Longevity Retreat. The company frames the project as a strategic expansion, emphasizing the prestige of Llanogrande, proximity to José María Córdova International Airport, and access to a large, growing wellness market valued at $6.8 trillion in 2024 and projected to reach $9.8 trillion by 2029. The acquisition is structured as an all-stock, related-party transaction, with the number of shares to be set by an independent appraisal; the seller is BSD SAS, owned by BIOM's CEO Jessika Wiesner. Management highlights the transaction as hard-asset growth without cash outlay, and stresses multiple potential revenue streams, including accommodation, wellness programs, spa services, and nutraceutical sales. The company also references a letter of intent to acquire Biomolecular Life LLC to support the retreat’s offerings. The announcement is optimistic, with detailed language about intended services and market opportunity, but provides no operational or financial specifics beyond the transaction structure and macro market data.

What the data suggests

The only concrete milestone is the agreement to acquire land via an all-stock, related-party transaction, with the share count to be determined by independent appraisal. No value for the property or number of shares is disclosed, leaving the financial impact undefined. The project is in a pre-construction phase, with construction anticipated to begin in January 2027 and opening targeted for Q1 2028, both contingent on financing, permitting, and regulatory approvals. The site’s proximity to an airport that handled over 14 million passengers in 2025, including 4.2 million international travelers, is cited as a competitive advantage. The company references the global wellness economy’s projected growth from $6.8 trillion in 2024 to $9.8 trillion by 2029 (7.6% CAGR), but does not link this to its own addressable market or provide demand validation. All operational and revenue projections are aspirational, with no evidence of secured funding, construction contracts, or regulatory progress. The disclosure is high on narrative and market context, but low on company-specific financials or execution detail.

Analysis

The announcement is framed in highly positive terms, emphasizing the prestige of the location, the scale of the global wellness market, and the company's strategic expansion. However, the only realised milestone is the agreement to acquire land via an all-stock, related-party transaction, with the number of shares still undetermined and subject to independent appraisal. All operational benefits—construction, opening, and revenue generation—are projected for 2027-2028 or later, and are contingent on financing, permitting, and regulatory approvals. The release repeatedly references the potential appeal to affluent travelers and the integration of advanced wellness technologies, but provides no evidence of secured funding, construction contracts, or operational readiness. The use of global market size figures and aspirational language about future offerings inflates the perceived opportunity, while the actual progress is limited to a preliminary land acquisition. The capital intensity is high, as the project requires significant development before any returns, and the timeline for benefit realization is long-term.

Risk flags

• ●Execution risk is high, as the project is at a pre-construction stage with construction not expected to begin until January 2027, and opening targeted for Q1 2028, both contingent on financing, permits, and regulatory approvals. Delays or failure to secure these could push timelines further out or jeopardize the project.
• ●The transaction is a related-party deal, with the land currently owned by BSD SAS, controlled by BIOM's CEO Jessika Wiesner. This raises governance and valuation risks, as the number of shares to be issued will be set by an independent appraisal, but no value or methodology is disclosed.
• ●No financial details are provided regarding the appraised value of the property, the number of shares to be issued, or the expected capital requirements for development. This lack of transparency makes it impossible to assess dilution risk, balance sheet impact, or the project's financial viability.
• ●The company relies heavily on macro market growth figures ($6.8 trillion in 2024, projected $9.8 trillion by 2029, 7.6% CAGR) to frame the opportunity, but provides no evidence of demand for its specific offering, nor any secured customers, partners, or operational readiness.
• ●All operational and revenue projections are aspirational, with no evidence of secured project financing, construction contracts, or regulatory progress. The risk of narrative inflation is high if these milestones are not met.

Bottom line

This announcement signals only an agreement to acquire land for a luxury wellness retreat in Llanogrande, Colombia, via an all-stock, related-party transaction with the CEO’s company, with the share count and property value still undetermined. All operational milestones—construction, opening, and revenue generation—are at least 14 to 17 months away and depend on securing financing, permits, and regulatory approvals. The company leans heavily on global wellness market growth statistics to frame the opportunity, but provides no company-specific financials, demand validation, or evidence of execution capability. The lack of transparency on valuation and dilution, combined with the related-party nature of the deal, adds governance and financial risk. Investors should treat this as a very early-stage, high-risk narrative with no near-term catalysts or tangible value creation until at least 2028. The most important takeaway is that all material benefits are long-dated and highly contingent, with no clarity yet on the project's financial impact or feasibility.

Announcement summary

(OTC:BIOM) Biomolecular Life Holdings, Inc. announced it has agreed to acquire land in Llanogrande, Rionegro, Antioquia, Colombia, for the development of a next-generation Biomolecular Wellness Spa and Longevity Retreat. The property is currently held by BSD SAS, a Colombian company owned by Jessika Wiesner, President and Chief Executive Officer of Biomolecular Life Holdings, Inc. The acquisition is structured as an all-stock transaction, with the number of BIOM shares to be determined by an independent appraisal of the property. As the seller is controlled by the company's CEO, this is a related-party transaction. Construction is anticipated to begin in January 2027, with the opening targeted for the first quarter of 2028, subject to financing, permitting, regulatory approvals, and construction timelines. The planned destination is located approximately 10 minutes from José María Córdova International Airport (MDE), which handled more than 14 million passengers in 2025, including more than 4.2 million international travelers. Management believes the Llanogrande project offers hard-asset growth without a cash outlay, as the land is being acquired in an all-stock transaction, expected to add a real estate asset to the company's balance sheet while preserving cash for development. Llanogrande is described as one of the most prestigious and highest-valued residential markets in Antioquia, home to luxury estates, country clubs, and premium developments. The planned retreat is designed to combine accommodation, wellness programs, spa services, and sales of the Biomolecular Life nutraceutical line, supported by the company's letter of intent to acquire Biomolecular Life LLC. The global wellness economy is valued at $6.8 trillion in 2024 and is projected to reach nearly $9.8 trillion by 2029, representing growth of about 7.6% a year, according to the Global Wellness Institute. The planned Biomolecular Wellness Spa is expected to incorporate personalized biomolecular wellness programs, advanced wellness technologies, longevity-oriented wellness programs, personalized nutritional strategies, wellness assessments, spa and rejuvenation experiences, and multi-day wellness retreats. The company believes the location could appeal to international wellness travelers, affluent individuals, health-conscious professionals, luxury travelers, and visitors interested in personalized wellness and longevity-oriented experiences. The Llanogrande project is part of Biomolecular Life Holdings' broader expansion strategy and is envisioned as a foundation for future expansion of its biomolecular wellness ecosystem. Jessika Wiesner, President and Chief Executive Officer, stated that acquiring the land in Llanogrande represents a significant milestone in the company's strategic expansion and highlighted the area's exclusivity, affluent communities, and natural surroundings. The company manages the marketing of the Biomolecular Life nutraceutical product line and has signed a letter of intent to acquire Biomolecular Life LLC.

Disagree with this article?